GlassScriptPhysician profile
James B Tucker
NPI 1922020197
$788.43
in general payments reported to CMS, 2019-2025
21 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.36 · 2021: $16.22 · 2022: $62.35 · 2023: $212 · 2024: $243 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $139.50 | 2022-2024 | |
| Novo Nordisk INC | $90.17 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $87.46 | 2023-2025 | Ubrelvy |
| Lilly USA, LLC | $49.78 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $43.07 | 2022-2024 | Pediarix, Rotarix, Bexsero |
| Exact Sciences Corporation | $40.26 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $37.15 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.30 | 2022-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $34.29 | 2023-2024 | Trintellix |
| Amgen INC. | $31.71 | 2019-2024 | Repatha, Otezla |
| Edwards Lifesciences Corporation | $30.84 | 2025 | |
| Ferring Pharmaceuticals INC. | $21.65 | 2024 | Rebyota |
| Astrazeneca Pharmaceuticals LP | $20.28 | 2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $19.87 | 2024 | |
| Phathom Pharmaceuticals, INC. | $17.70 | 2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $16.56 | 2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.79 | 2025 | Caplyta |
| Axonics, INC. | $15.62 | 2023 | Bulkamid |
| Novartis Pharmaceuticals Corporation | $15.49 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.07 | 2024 | Xifaxan |
| Ironshore Pharmaceuticals INC. | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.